About this item:

65 Views | 21 Downloads

Author Notes:

Lauren A. V. Orenstein, MD, Department of Dermatology, Emory University, 1525 Clifton Road, Atlanta, GA 30322. Email: lauren.orenstein@emory.edu

LAVO has served as an investigator Chemocentryx; consulted for Chemocentryx, MedEd Consulting, Huron Consulting Group; and received lecture honoraria from Frontline Medical Communications. MAL has served on advisory boards for Abbvie, Janssen and Viela Bio, and consulted for Almirall, BSN, Incyte, Janssen, Kymera, and Xbiotech. VS serves as a consultant for Releviate. AMB, KTS, ZSP and CAY report no disclosures.

Subject:

Research Funding:

LAVO’s participation was supported in part by the Building Interdisciplinary Research Careers in Women’s Health of the National Institutes of Health under Award number K12D085850.

The funding agency did not have any input in the study design, data collection, data analysis, manuscript publication, or publication decisions. VS’ participation was supported in part by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award number UL1TR002378 and KL2TR002381. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Dermatology
  • acute pain
  • chronic pain
  • hidradenitis suppurativa
  • neuropathic
  • nociceptive
  • pain management
  • treatment
  • ALPHA-LIPOIC ACID
  • NONSTEROIDAL ANTIINFLAMMATORY DRUGS
  • QUALITY-OF-LIFE
  • LOW-BACK-PAIN
  • NEUROPATHIC PAIN
  • COMMITMENT THERAPY
  • DOUBLE-BLIND
  • OSTEOARTHRITIS
  • EFFICACY
  • SAFETY

Pain management in hidradenitis suppurativa and a proposed treatment algorithm

Tools:

Journal Title:

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Volume:

Volume 85, Number 1

Publisher:

, Pages 187-199

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Pain contributes substantially to reduced quality of life in individuals living with hidradenitis suppurativa (HS). Although improved understanding of HS pathogenesis and treatment has resulted in improved evidence-based HS management guidelines, comprehensive pain management guidelines have yet to be developed. Few HS-specific data exist to guide pharmacologic analgesia; however, recognizing HS pain as either acute or chronic and predominantly nociceptive (aching and gnawing pain due to tissue damage) versus neuropathic (burning-type pain due to somatosensory nervous system dysfunction) provides a conceptual framework for applying outside pain management practices to HS management. This article incorporates the best available evidence from the HS and pain literature to propose an HS pain algorithm that integrates psychological, pharmacologic, and complementary and alternative treatment modalities.

Copyright information:

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/rdf).
Export to EndNote